Join our daily newsletter At The Bell to receive exclusive market insights
Biotech company Actinogen has expanded clinical development for the company’s lead drug candidate ‘Xanamem’.
The company made the decision after an extensive scientific, commercial and testing review of the drug showed positive projections.
Xanamem is a drug aimed at treating impairment in neurological diseases such as Alzheimer’s, schizophrenia and bipolar disorder.
The drug targets raised cortisol levels in the brain and inhibits excess production of it.
Excessive cortisol production in the brain is common amongst mood disorder patients.
Xanamem has shown positive results on genetically identical mouse models and showed maintained improved cognitive function for 41 weeks.
Second phase trials of Alzheimer’s patients using Xanamem began in 2017.
The company estimates roughly 24 million Americans are living with mood disorders and this research shows significant market opportunity.
A specialist advisory board will be assigned to establish the company’s future clinical development plan for the drug.
